Drug intelligence / Profile preview

yuxintine

Development stage: Phase 2
Lead developer: Shanghai Innovative Research Center of Traditional Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

Yuxintine is an investigational drug developed for the treatment of depression. Clinical studies have evaluated Yuxintine capsules at different doses to determine their efficacy in treating depressive disorders. Research findings indicate that Yuxintine exhibits antidepressant effects comparable to fluoxetine (Prozac), a widely used selective serotonin reuptake inhibitor (SSRI) in clinical practice. The precise mechanism of action has not been explicitly detailed, but its similar efficacy to fluoxetine suggests it may act on serotonergic pathways or related neurotransmitter systems[3][4].

Beyond the preview

Go deeper on yuxintine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on yuxintine.

Explore the full profile